Keyword
2.02E+11
2.02E+11
2.02E+13
2019 003327 37
2019 003327-37
2019-003327 37
2019003327-37
2019-00332737
2019-003327-37
2021 003936 10
2021 003936-10
2021-003936 10
2021003936-10
2021-00393610
2021-003936-10
2023 504036 17 00
2023 504036-17-00
2023-504036 17-00
2023-504036-17 00
2023504036-17-00
2023-50403617-00
2023-504036-1700
2023-504036-17-00
A 1195425
A 1195425.0
A 11954250
A1195425
A-1195425
A1195425.0
A-1195425.0
A11954250
A-11954250
ABBV GMAB 3013
ABBV GMAB3013
ABBV GMAB-3013
ABBVGMAB 3013
ABBV-GMAB 3013
ABBVGMAB3013
ABBVGMAB-3013
ABBV-GMAB3013
ABBV-GMAB-3013
Acalabrutinib
Acalabrutinib
Acalabrutinib
Acalabrutinib
Acalabrutinib
Acalabrutinib maleate
Axatillimab
Axatillimab
Axatillimab
B-cell lymphoma 2
B-cell lymphoma 2 mutant
B-cell lymphoma 2 mutated
B-cell lymphoma 2-m
B-cell lymphoma 2-mutant
B-cell lymphoma 2-mutated
B-cell lymphoma2
B-cell lymphoma-2
B-cell lymphoma2 mutant
B-cell lymphoma-2 mutant
B-cell lymphoma2 mutated
B-cell lymphoma-2 mutated
B-cell lymphoma2-m
B-cell lymphoma-2-m
B-cell lymphoma2-mutant
B-cell lymphoma-2-mutant
B-cell lymphoma2-mutated
B-cell lymphoma-2-mutated
BCL 2
BCL 2 mutant
BCL 2 mutated
BCL 2-m
BCL 2-mutant
BCL 2-mutated
BCL2
BCL-2
BCL-2
BCL-2
BCL2 mutant
BCL-2 mutant
BCL2 mutated
BCL-2 mutated
BCL2-m
BCL-2-m
BCL2-mutant
BCL-2-mutant
BCL2-mutated
BCL-2-mutated
BGB11417
BGB11417
BGB11417
BGB-11417
BGB-11417
BGB-11417
BGB-11417
BGB-11417
Bi specific Ab
Bi specific Abs
Bi specific Antibodies
Bi specific Antibody
BIIB 135
BIIB135
BIIB-135
Bispecific Ab
Bi-specific Ab
Bispecific Abs
Bi-specific Abs
Bispecific Antibody
Bispecific Antibody
Bispecific Antibody
Bispecific Antibody
Bispecific Antibody
Brexu cel
brexucabtagene autoleucel
brexucabtagene autoleucel
brexucabtagene autoleucel
brexucabtagene autoleucel
brexucabtagene autoleucel
Brexucabtageneautoleucel
Brexucel
Brexu-cel
Bruton tyrosine kinase
Bruton tyrosine kinase Degrader
Bruton tyrosine kinase-Degrader
Brutons tyrosine kinase
Bruton's tyrosine kinase
Brutons tyrosine kinase Degrader
Bruton's tyrosine kinase Degrader
Brutons tyrosine kinase-Degrader
Bruton's tyrosine kinase-Degrader
BTK
BTK
BTK
BTK degrader
BTK degrader
BTK degrader
BTK degrader
BTK degrader
BTK-degrader
CAR-T
CAR-T
CAR-T
CAR-T
Chronic Lymphocytic Leukemia 16
Chronic Lymphocytic Leukemia16
Chronic Lymphocytic Leukemia-16
CLL
CLL
CLL
CLL
CLL 16
CLL16
CLL-16
CLL-16
CLL-16
CO41685
CRISTALLO
CRISTALLO
CRISTALLO
D8220C00027
Epcoritamab
Epcoritamab
Epcoritamab
Epcoritamab
Epcoritamab
JCAR 017
JCAR-017
Lisaftoclax
Lisaftoclax
Lisaftoclax
Lisaftoclax
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Loncastuximab Tesirine
Loncastuximab Tesirine
Loncastuximab Tesirine
Loncastuximab Tesirine
Loncastuximab Tesirine
loncastuximab tesirine lpyl
loncastuximab tesirine-lpyl
loncastuximab-tesirine lpyl
loncastuximab-tesirine-lpyl
LY 3527727
LY3527727
LY-3527727
MAJIC
MAJIC
MAJIC
mB-cell lymphoma 2
mB-cell lymphoma -2
mB-cell lymphoma2
mBCL 2
mBCL2
mBCL-2
Measurable Residual Disease
Mosunetuzumab
Mosunetuzumab
Mosunetuzumab
Mosunetuzumab
Mosunetuzumab
MRD
MRD
MRD
MRD
MRD
mutant (m) B-cell lymphoma 2
mutant (m) B-cell lymphoma2
mutant (m) B-cell lymphoma-2
mutant (m) BCL 2
mutant (m) BCL2
mutant (m) BCL-2
mutant (m)B-cell lymphoma 2
mutant (m)B-cell lymphoma2
mutant (m)B-cell lymphoma-2
mutant (m)BCL 2
mutant (m)BCL2
mutant (m)BCL-2
mutant (m)BCL-2
mutant (m)BCL-2
mutant B-cell lymphoma 2
mutant B-cell lymphoma2
mutant B-cell lymphoma-2
mutant BCL 2
mutant BCL2
mutant BCL-2
mutated (m) B-cell lymphoma 2
mutated (m) B-cell lymphoma2
mutated (m) B-cell lymphoma-2
mutated (m) BCL 2
mutated (m) BCL2
mutated (m) BCL-2
mutated (m)B-cell lymphoma 2
mutated (m)B-cell lymphoma2
mutated (m)B-cell lymphoma-2
mutated (m)BCL 2
mutated (m)BCL2
mutated B-cell lymphoma 2
mutated B-cell lymphoma2
mutated B-cell lymphoma-2
mutated BCL 2
mutated BCL2
mutated BCL-2
NCT04285567
NCT05057494
NCT05197192
Nemtabrutinib
Nemtabrutinib
Nemtabrutinib
Nemtabrutinib
NX-2127
NX-2127
NX-2127
NX-2127
NX-5948
NX-5948
NX-5948
NX-5948
Orelabrutinib
Orelabrutinib
Orelabrutinib
Orelabrutinib
Orelabrutinib
pirtobrutinib
pirtobrutinib
pirtobrutinib
pirtobrutinib
pirtobrutinib
redirected T cell
redirected T cells
redirected T-cell
redirected T-cells
redirecting T cell
redirecting T cells
redirecting T-cell
redirecting T-cells
redirecting-T-cell
redirecting-T-cells
redirection of T cell
redirection of T cells
redirection of T-cell
redirection of T-cells
RG 7828
RG7828
RG-7828
RO 5537382
RO 7030816
RO5537382
RO-5537382
RO7030816
RO-7030816
RXC 005
RXC005
RXC-005
Sonrotoclax
T cell redirecition
T-cell redirection
T-cell redirection
T-cell redirection
venetoclax
venetoclax
venetoclax
venetoclax
venetoclax
zanubrutinib
zanubrutinib
zanubrutinib
zanubrutinib
zilovertamab
zilovertamab
zilovertamab
zilovertamab
zilovertamab vedotin
zilovertamab vedotin
zilovertamab vedotin
zilovertamab vedotin
